China Intravenous Solutions Market Overview, 2030

In Chinese hospitals and clinics, infusion fluids are shifting from basic saline drips to advanced nutrient and electrolyte blends over recent decades. Early usage began in the mid-20th century to treat dehydration and support surgical recovery. Practitioners then faced purity inconsistencies and contamination risks, pushing manufacturers to develop sterile, factory-prepared mixes like balanced salts, total and peripheral parenteral nutrition (TPN/PPN), and drug-infused solutions. These products are made in cleanrooms, with multi-stage filtration, heat sterilization, and aseptic bag filling. Medical staff deploys them in hospitals, outpatient centers, emergency departments, dialysis clinics, and increasingly in home-based care. The infusions deliver fluids, electrolytes, glucose, medications, and nutrients directly into the bloodstream to correct hydration, stabilize blood pressure, enhance surgical outcomes, and support chronic and oncology patients who cannot eat. Over 10–20 years, China saw advancements like non-PVC packaging, dual-chamber bags, and smart pumps with dosage control. National motivations include rapid aging, rising chronic disease rates, and government healthcare investment slated to reach 7% of GDP by 2025. Technological development hubs in Shanghai and Wuhan focus on formula optimization for hot, humid conditions and robust packaging. Initiatives by the National Health Commission and NMPA eased approval for smart infusion systems. Despite initial delays in adopting complex nutrient blends due to validation gaps, collaboration with U.S. and European firms enabled technology transfer. Local funding for R&D bolstered product quality and reduced import reliance, especially for bag films and infusion pumps. Pilot programs in Beijing and Guangzhou demonstrated system reliability, helping build trust and enabling broader use across hospitals and home-care networks.

According to the research report ""China Intravenous Solutions Market Overview, 2030,"" published by Bonafide Research, the China Intravenous Solutions market is anticipated to grow at more than 8.90% CAGR from 2025 to 2030. This expansion is driven by chronic illnesses, aging population, hospital upgrades, and rising home-infusion care. A cultural shift toward wellness drips at clinics also fuels demand. During COVID, delays in polymer film and tubing imports disrupted production but were offset by increasing local manufacturing capacities and eased NMPA regulations for essential health products. China now sources raw materials such as bag films from the U.S. and Germany, and distributes finished fluids across Asia Pacific. Major players include Baxter (now exiting China due to local competition), Fresenius Kabi, Otsuka, and B. Braun, offering ready-to-use electrolyte and nutrition bags, smart pumps, and integrated infusion systems. They focus on wider production, digital traceability, and tailored packs. Emerging manufacturers like JW Life Sciences focus on TPN and PPN solutions, benefiting from domestic partnerships but still scaling validation efforts. Outsourced facilities and logistics providers support quality control, clean-room filling, cold-chain transport, and NMPA certifications. Production concentrates in coastal provinces like Guangdong and Jiangsu, while demand is highest in populous eastern cities. Rising public-private hospital investment and national health plans led to stronger regional distribution.

The China intravenous (IV) market segmented by product type primarily consists of Total Parenteral Nutrition (TPN) and Peripheral Parenteral Nutrition (PPN), both playing critical roles in addressing the nutritional needs of patients unable to meet their requirements through oral or enteral feeding. TPN dominates the Chinese market due to its application in patients requiring comprehensive and long-term nutritional support, such as those suffering from severe gastrointestinal disorders, cancer, critical illnesses, or post-major surgeries. Administered via central venous catheters, TPN enables delivery of high-concentration nutrients and complex formulations, facilitating personalized nutrition tailored to patients’ metabolic demands. The rapid urbanization and increasing prevalence of chronic diseases in China, alongside an expanding aging population, are major factors driving the demand for TPN. Additionally, the Chinese government’s increasing focus on healthcare infrastructure and the rising adoption of advanced medical technologies in hospitals contribute to the growth of TPN usage. Meanwhile, PPN serves as a viable alternative for short-term or less severe cases, delivered through peripheral veins with lower nutrient concentrations and reduced risks compared to TPN, making it suitable for acute care and transitional nutritional therapy. Despite limitations on nutrient density and administration duration, PPN’s role remains significant in early-stage malnutrition management and outpatient care. Growing awareness among healthcare providers about the benefits of early nutritional intervention, combined with improvements in infusion technologies and compounding standards, are fostering market expansion for both product types. Furthermore, emerging homecare and outpatient infusion services are broadening accessibility. However, challenges such as the need for skilled medical staff and concerns around infection control persist.

The China intravenous (IV) market segmented by composition reflects the increasing complexity and diversification of parenteral nutrition tailored to a wide spectrum of patient needs. Carbohydrates, primarily in the form of dextrose solutions, form the fundamental energy source in IV formulations, essential for meeting patients’ caloric requirements, especially during recovery from surgery, trauma, or severe illness. The rising volume of surgical procedures and critical care admissions in China drive significant carbohydrate usage in clinical nutrition. Vitamins and minerals are indispensable components, included to prevent deficiencies and support metabolic functions, immune response, and wound healing, typically administered as part of multi-trace element and vitamin complexes conforming to international nutritional standards. The use of single dose amino acids is increasingly prevalent, particularly in the management of protein-energy malnutrition common in cancer patients and the elderly, aiding tissue repair and synthesis. China’s expanding oncology and geriatric populations are key drivers behind this growth. Parenteral lipid emulsions supply essential fatty acids and dense caloric intake, with the market witnessing a shift toward advanced multi-source lipid emulsions, such as those combining soybean, olive, and fish oils, which offer improved safety profiles and reduced inflammation risks, aligning with global clinical trends. The others segment includes electrolytes, buffers, and specialized additives tailored to patient-specific needs, including glutamine, antioxidants, and immunonutrients, which are gaining traction as personalized medicine advances. Increased regulatory oversight, improved hospital nutrition protocols, and investment in home infusion services support the availability and adoption of these complex compositions. The ongoing modernization of healthcare infrastructure and the rising prevalence of chronic diseases will continue to propel demand for balanced, safe, and effective IV nutrition solutions across China’s healthcare settings.

Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report
• Intravenous Solutions Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product Type
• Total Parenteral Nutrition
• Peripheral Parenteral Nutrition

By Composition
• Carbohydrates
• Vitamins and Minerals
• Single Dose Amino Acids
• Parenteral Lipid Emulsion
• Others Show more